
Sign up to save your podcasts
Or
Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF). Credit available for this activity expires: 9/29/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996906?ecd=bdc_podcast_libsyn_mscpedu
4
77 ratings
Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF). Credit available for this activity expires: 9/29/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996906?ecd=bdc_podcast_libsyn_mscpedu
131 Listeners
13 Listeners
323 Listeners
863 Listeners
496 Listeners
693 Listeners
18 Listeners
274 Listeners
254 Listeners
3,318 Listeners
260 Listeners
86 Listeners
1,084 Listeners
186 Listeners
513 Listeners
351 Listeners
59 Listeners
25 Listeners
287 Listeners